Forecasting News and Research

RSS

GHX Market Intelligence data increases growth of medical-surgical revenue through distribution by 6.42% in 2009

An analysis of medical-surgical sales through distribution conducted by GHX has found that among the top 100 U.S. medical-surgical manufacturers by dollar spend, those that use GHX Market Intelligence data grew medical-surgical revenue through distribution by an average of 6.42 percent in 2009, while non-users grew similarly classified revenue by an average of only 3.88 percent. Furthermore, GHX's analysis also found that those manufacturers employing more granular-level market data from GHX increased revenue at a faster rate than those using higher-level data.

31 Jul 2010

NxStage Medical second-quarter net revenue increases 21% to $44.0 million

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported record financial results for the second quarter of 2010 ended June 30, 2010, with total revenue above the top end of its guidance range.

23 Jul 2010

BioTime announces 21 new stem cell products for sale

BioTime, Inc. announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line.

22 Jul 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan Corporation, plc today reported its second quarter and first half 2010 financial results.

22 Jul 2010

Alcon Japan goes live with Varicent incentive compensation and sales performance management solutions

The leading innovator in incentive compensation (ICM) and sales performance management (SPM) solutions, Varicent Software Incorporated, announced today a successful "go live" of Varicent for Alcon Japan Ltd.

21 Jul 2010

Alcon selects Varicent for sales performance management solutions

Varicent Software Incorporated, the leading innovator in incentive compensation (ICM) and sales performance management (SPM) solutions, announced today that it will provide its innovative solutions to Alcon, the world's largest eye-care company.

15 Jul 2010

Varian adopts Varicent for administering Sales Performance Management needs

Varicent Software Incorporated, the leading innovator in incentive compensation (ICM) and sales performance management (SPM) solutions, announced today that a business unit within Varian Medical Systems, the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions, has selected Varicent for administering its complex sales incentive compensation plans and sales performance management activities.

14 Jul 2010

Researchers detail innovations that may facilitate earlier detection, improved public health preparedness

With current public health threats ranging from swine flu to bioterrorism to environmental contamination, innovations that better predict disease outbreaks have vast potential to protect the public. In a paper published online in advance of print on July 6 in Emerging Health Threats Journal, public health researchers describe their vision for the future of disease surveillance, detailing innovations on the horizon that may facilitate earlier detection and improved public health preparedness.

14 Jul 2010

Slow-starting high risk pools look for bigger wave of enrollees, other reform issues

States have seen a "slow trickle" of enrollees for new federally funded high-risk pools but are expecting more to begin enrolling as word spreads about the coverage option, Politico reports.

14 Jul 2010

Hot temperature extremes could become frequent events in the U.S. by 2039: GRL study

Exceptionally long heat waves and other hot events could become commonplace in the United States in the next 30 years, according to a new study by Stanford University climate scientists.

9 Jul 2010

Researchers develop system to forecast ash cloud evolution from Iceland's Eyjafjallajökull volcano

Researchers at the Universidad Politécnica de Madrid's Facultad de Informática have developed a system to forecast the evolution of the ash cloud from Iceland's Eyjafjallajökull volcano.

14 Jun 2010

TransEnterix selects SYSPRO ERP software

SYSPRO, the leading provider of visionary, pragmatic ERP software, has today announced that TransEnterix, a fast-growing medical device manufacturer based in Durham, North Carolina, has selected SYSPRO ERP software after a lengthy selection process that included a thorough analysis of seven mid-range ERP software providers.

11 Jun 2010

PAREXEL experts to present on biopharmaceutical industry issues at 46th DIA

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that several of its experts will present on important industry issues at the Drug Information Association (DIA) 46th Annual Meeting, being held from June 13 – 17, 2010 in Washington, DC.

From Parexel 10 Jun 2010

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Biomedical/Clinical Engineering practice improves healthcare: Health Association Nova Scotia

The week, May 23 to May 29, is National Biomedical/Clinical Engineering Appreciation Week and celebrations across the country are recognizing the importance of this field to improving healthcare and the contributions of its practitioners.

27 May 2010

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.

6 May 2010